secwatch.observer — SEC 8-K summary
======================================

Issuer:     Sana Biotechnology, Inc. (SANA)
CIK:        0001770121
Form:       8-K
Filed at:   2023-03-16T23:59:59+00:00
Accession:  0001564590-23-003795
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Sana reports Q4 net loss $80.4M; cash $434M; SC291 IND cleared, expects clinical data this year
--------------------------------------------------------------------------------

- Net loss Q4 2022 $80.4M ($0.42/sh) vs $110.7M ($0.60/sh) in Q4 2021; FY2022 net loss $269.5M ($1.43/sh).
- Cash and marketable securities $434.0M at Dec 31, 2022, down from $746.9M; cash runway into 2025.
- SC291 (CD19-targeted allogeneic CAR T) IND cleared; initial clinical data expected in 2023.
- Plans to move manufacturing to Bothell, WA; expects ~$100M cost savings versus Fremont build-out.
- Non-GAAP operating cash burn FY2022 $288.3M vs $209.6M; restructuring costs in Q4 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1770121/000156459023003795/0001564590-23-003795-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1770121/000156459023003795/sana-8k_20230316.htm
  HTML page:      https://secwatch.observer/filing/0001564590-23-003795

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer